SSKI solution is administered for therapy with which radiopharmaceutical?

The use of SSKI (saturated solution of potassium iodide) in conjunction with radiopharmaceutical therapy is primarily associated with 131-I sodium iodide. SSKI provides a protective measure against potential thyroid uptake of iodide from the environment and helps to reduce the risk of radiation exposure to the thyroid gland when using therapies that involve iodine-131.

When a patient is treated with 131-I sodium iodide, SSKI is administered prior to the therapy. This is because the thyroid gland has a natural affinity for iodine, and in the case of treatment with radioactive iodine, there is a risk that non-radioactive iodine could accumulate in the gland instead of the therapeutic dose of radioactive iodine. Administering SSKI saturates the thyroid with stable iodine, effectively blocking the uptake of radioactive iodine and minimizing potential side effects.

In the context of the other options, while 131-I tositumomab is also related to iodine-131, it is a monoclonal antibody therapy that does not typically require the same kind of protective pre-treatment as with 131-I sodium iodide. The other radiopharmaceuticals listed, like 153-Sm lexidronam and 89-Sr chloride, do not involve iodine in their